<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="inad" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">inad</book-part-id>
      <title-group>
        <title><italic toggle="yes">PLA2G6</italic>-Associated Neurodegeneration</title>
        <alt-title alt-title-type="alt-title">Synonyms: NBIA2, <italic toggle="yes">PLA2G6</italic>-Related Disorders, PLAN</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gregory</surname>
            <given-names>Allison</given-names>
          </name>
          <degrees>MS, CGC</degrees>
          <aff>Molecular &#x00026; Medical Genetics<break/>Oregon Health &#x00026; Science University<break/>Portland, Oregon</aff>
          <email>gregorya@ohsu.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kurian</surname>
            <given-names>Manju A</given-names>
          </name>
          <degrees>MA, MRCPCH, PhD</degrees>
          <aff>Molecular Neurosciences<break/>Developmental Neurosciences<break/>UCL-Great Ormond Street Institute of Child Health<break/>London, United Kingdom</aff>
          <email>manju.kurian@ucl.ac.uk</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Maher</surname>
            <given-names>Eamonn R</given-names>
          </name>
          <degrees>MD, FRCP, FMedSci</degrees>
          <aff>Department of Medical Genetics<break/>University of Cambridge<break/>Cambridge, United Kingdom</aff>
          <email>erm1000@cam.ac.uk</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hogarth</surname>
            <given-names>Penelope</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Neurology and Molecular &#x00026; Medical Genetics<break/>Oregon Health &#x00026; Science University<break/>Portland, Oregon</aff>
          <email>hogarthp@ohsu.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hayflick</surname>
            <given-names>Susan J</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Molecular &#x00026; Medical Genetics, Pediatrics, and Neurology<break/>Oregon Health &#x00026; Science University<break/>Portland, Oregon</aff>
          <email>hayflick@ohsu.edu</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>19</day>
          <month>6</month>
          <year>2008</year>
        </date>
        <date date-type="updated">
          <day>23</day>
          <month>3</month>
          <year>2017</year>
        </date>
        <date date-type="revised">
          <day>19</day>
          <month>3</month>
          <year>2015</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="pink1-pd" document-type="chapter"><italic toggle="yes">PINK1</italic> Type of Young-Onset Parkinson Disease</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="pmd" document-type="chapter">
<italic toggle="yes">PLP1</italic>-Related Disorders</related-object>
      <abstract id="inad.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p><italic toggle="yes">PLA2G6</italic>-associated neurodegeneration (PLAN) comprises a continuum of three phenotypes with overlapping clinical and radiologic features:</p>
          <list list-type="bullet">
            <list-item>
              <p>Infantile neuroaxonal dystrophy (INAD)</p>
            </list-item>
            <list-item>
              <p>Atypical neuroaxonal dystrophy (atypical NAD)</p>
            </list-item>
            <list-item>
              <p><italic toggle="yes">PLA2G6</italic>-related dystonia-parkinsonism</p>
            </list-item>
          </list>
          <p>INAD usually begins between ages six months and three years with psychomotor regression or delay, hypotonia, and progressive spastic tetraparesis. Many affected children never learn to walk or lose the ability shortly after attaining it. Strabismus, nystagmus, and optic atrophy are common. Disease progression is rapid, resulting in severe spasticity, progressive cognitive decline, and visual impairment. Many affected children do not survive beyond their first decade.</p>
          <p>Atypical NAD shows more phenotypic variability than INAD. In general, onset is in early childhood but can be as late as the end of the second decade. The presenting signs may be gait instability, ataxia, or speech delay and autistic features, which are sometimes the only evidence of disease for a year or more. Strabismus, nystagmus, and optic atrophy are common. Neuropsychiatric disturbances including impulsivity, poor attention span, hyperactivity, and emotional lability are also common. The course is fairly stable during early childhood and resembles static encephalopathy but is followed by neurologic deterioration between ages seven and 12 years.</p>
          <p><italic toggle="yes">PLA2G6</italic>-related dystonia-parkinsonism has a variable age of onset, but most individuals present in early adulthood with gait disturbance or neuropsychiatric changes. Affected individuals consistently develop dystonia and parkinsonism (which may be accompanied by rapid cognitive decline) in their late teens to early twenties. Dystonia is most common in the hands and feet but may be more generalized. The most common features of parkinsonism in these individuals are bradykinesia, resting tremor, rigidity, and postural instability.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of <italic toggle="yes">PLA2G6</italic>-associated neurodegeneration is established in a proband by identification of biallelic pathogenic variants in <italic toggle="yes">PLA2G6</italic> on molecular genetic testing. The diagnosis of INAD or atypical NAD can be established in a proband with no identified <italic toggle="yes">PLA2G6</italic> pathogenic variants by electron microscopic examination of nerve biopsies for dystrophic axons (axonal spheroids).</p>
        </sec>
        <sec>
          <title>Management</title>
          <p>
            <italic toggle="yes">Treatment of manifestations:</italic>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Individuals with INAD and atypical NAD. Routine pharmacologic treatment of spasticity and seizures; trial of oral or intrathecal baclofen for dystonia associated with atypical INAD; treatment by a psychiatrist for those with later-onset neuropsychiatric symptoms; fiber supplements and/or stool softener treatment for constipation; control of secretions with transdermal scopolamine patch as needed; feeding modifications as needed to prevent aspiration pneumonia and achieve adequate nutrition.</p>
            </list-item>
            <list-item>
              <p>Individuals with <italic toggle="yes">PLA2G6</italic>-related dystonia-parkinsonism. Consider treatment with dopaminergic agents; treatment of neuropsychiatric symptoms by a psychiatrist; evaluation by physical therapy for management of postural instability and gait difficulties; occupational therapy to assist with activities of daily living; feeding modifications as needed to prevent aspiration pneumonia and achieve adequate nutrition.</p>
            </list-item>
          </list>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Early physical therapy and orthopedic management to prevent contractures as the disease progresses; body temperature monitors may be required for individuals with progressive autonomic involvement to identify dangerous fluctuations in core body temperature.</p>
          <p><italic toggle="yes">Surveillance:</italic> Periodic assessment of vision and hearing of nonverbal children is indicated as needed to determine the level of sensory deficits.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p><italic toggle="yes">PLA2G6</italic>-associated neurodegeneration is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk family members and prenatal testing for pregnancies at increased risk are possible if the pathogenic variants in the family are known.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="inad.GeneReview_Scope">
        <title><italic toggle="yes">GeneReview</italic> Scope</title>
        <table-wrap id="inad.Tc" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_inad.Tc_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1"><italic toggle="yes">PLA2G6</italic>-Associated Neurodegeneration: Included Phenotypes&#x000a0;<sup>1</sup></th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_inad.Tc_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Infantile neuroaxonal dystrophy (INAD)</p></list-item><list-item><p>Atypical neuroaxonal dystrophy (atypical NAD)</p></list-item><list-item><p><italic toggle="yes">PLA2G6</italic>-related dystonia-parkinsonism</p></list-item></list>
</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>For synonyms and outdated names see <xref ref-type="sec" rid="inad.Nomenclature">Nomenclature</xref>.</p>
            </fn>
            <fn id="inad.TF.c.1">
              <label>1. </label>
              <p>For other genetic causes of these phenotypes see <xref ref-type="sec" rid="inad.Differential_Diagnosis">Differential Diagnosis</xref>.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="inad.Diagnosis">
        <title>Diagnosis</title>
        <sec id="inad.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p><italic toggle="yes">PLA2G6</italic>-associated neurodegeneration (PLAN) comprises a continuum of three phenotypes with overlapping clinical and radiologic features:</p>
          <list list-type="bullet">
            <list-item>
              <p>Infantile neuroaxonal dystrophy (INAD)</p>
            </list-item>
            <list-item>
              <p>Atypical neuroaxonal dystrophy (atypical NAD)</p>
            </list-item>
            <list-item>
              <p><italic toggle="yes">PLA2G6</italic>-related dystonia-parkinsonism</p>
            </list-item>
          </list>
          <sec id="inad.Infantile_Neuroaxonal_Dystrophy_INA">
            <title>Infantile Neuroaxonal Dystrophy (INAD)</title>
            <p><italic toggle="yes">PLA2G6</italic>-associated INAD <bold>should be suspected</bold> in individuals with the following clinical, laboratory, radiographic, and neurophysiologic features.</p>
            <p>
              <bold>Clinical</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Onset before age three years</p>
              </list-item>
              <list-item>
                <p>Psychomotor regression (most common presenting feature)</p>
              </list-item>
              <list-item>
                <p>Early truncal hypotonia followed by spastic tetraparesis (usually with hyperreflexia in the early disease stages with progression to areflexia later in the disease course)</p>
              </list-item>
              <list-item>
                <p>Visual abnormalities: strabismus, nystagmus, optic atrophy</p>
              </list-item>
            </list>
            <p>
              <bold>Laboratory</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Elevated aspartate aminotransferase/alanine aminotransferase ratio</p>
              </list-item>
              <list-item>
                <p>Elevated lactate dehydrogenase</p>
              </list-item>
            </list>
            <p>
              <bold>Radiographic</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Cerebellar atrophy (see <xref ref-type="fig" rid="inad.F1">Figure 1</xref>)</p>
              </list-item>
              <list-item>
                <p>T<sub>2</sub>-weighted MRI of the brain: hypointense globus pallidus (indicating iron accumulation), cortical cerebellar hyperintensities consistent with cerebellar gliosis, white matter abnormalities, thin vertically oriented corpus callosum (see <xref ref-type="fig" rid="inad.F1">Figure 1</xref>), and hypertrophy of the clava [<xref ref-type="bibr" rid="inad.REF.illingworth.2014.183">Illingworth et al 2014</xref>, <xref ref-type="bibr" rid="inad.REF.almaawali.2016.1035">Al-Maawali et al 2016</xref>]</p>
              </list-item>
            </list>
            <p>
              <bold>Neurophysiologic</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>EMG (electromyogram). Evidence of denervation</p>
              </list-item>
              <list-item>
                <p>EEG (electroencephalogram). Fast rhythms</p>
              </list-item>
              <list-item>
                <p>VEP (visual evoked potential). Delayed with reduced amplitudes</p>
              </list-item>
              <list-item>
                <p>NCV (nerve conduction velocity). Distal axonal-type sensorimotor neuropathy</p>
              </list-item>
              <list-item>
                <p>Seizures that may present early or late in the disease course [<xref ref-type="bibr" rid="inad.REF.wu.2009.240">Wu et al 2009</xref>]</p>
              </list-item>
            </list>
          </sec>
          <sec id="inad.Atypical_Neuroaxonal_Dystrophy_NAD">
            <title>Atypical Neuroaxonal Dystrophy (NAD)</title>
            <p><italic toggle="yes">PLA2G6</italic>-associated atypical NAD) <bold>should be suspected</bold> in individuals with the following clinical, radiographic, and neurophysiologic features.</p>
            <p>
              <bold>Clinical</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Onset before age 20 years</p>
              </list-item>
              <list-item>
                <p>Psychomotor regression</p>
              </list-item>
              <list-item>
                <p>Gait abnormalities</p>
              </list-item>
              <list-item>
                <p>Prominent expressive language difficulties</p>
              </list-item>
              <list-item>
                <p>Psychiatric/behavioral abnormalities including autistic-like behavior</p>
              </list-item>
              <list-item>
                <p>Visual abnormalities: nystagmus, optic atrophy</p>
              </list-item>
              <list-item>
                <p>Spasticity (without preceding hypotonia)</p>
              </list-item>
              <list-item>
                <p>Joint contractures</p>
              </list-item>
              <list-item>
                <p>Progressive dystonia and dysarthria</p>
              </list-item>
              <list-item>
                <p>Disease progression slower than in INAD</p>
              </list-item>
            </list>
            <p>
              <bold>Radiographic</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Cerebellar atrophy</p>
              </list-item>
              <list-item>
                <p>T<sub>2</sub>-weighted MRI of the brain: hypointense globus pallidus (indicating iron accumulation)</p>
              </list-item>
            </list>
            <p>
              <bold>Neurophysiologic</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>VEP. Delayed with reduced amplitudes</p>
              </list-item>
              <list-item>
                <p>Seizures</p>
              </list-item>
            </list>
          </sec>
          <sec id="inad.PLA2G6Related_DystoniaParkinsonism">
            <title><italic toggle="yes">PLA2G6</italic>-Related Dystonia-Parkinsonism</title>
            <p><italic toggle="yes">PLA2G6</italic>-related dystonia-parkinsonism <bold>should be suspected</bold> in individuals with the following clinical and radiographic features.</p>
            <p>
              <bold>Clinical</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Onset varying from childhood to young adulthood</p>
              </list-item>
              <list-item>
                <p>Parkinsonism (tremor, bradykinesia, rigidity, and markedly impaired postural responses)</p>
              </list-item>
              <list-item>
                <p>Dystonia</p>
              </list-item>
              <list-item>
                <p>Dysarthria</p>
              </list-item>
              <list-item>
                <p>Autonomic involvement (e.g., cold/blue hands and feet, difficulty regulating core body temperature, constipation)</p>
              </list-item>
              <list-item>
                <p>Cognitive decline</p>
              </list-item>
              <list-item>
                <p>Neuropsychiatric changes</p>
              </list-item>
              <list-item>
                <p>Initial dramatic response to dopaminergic treatment followed by the early development of dyskinesias</p>
              </list-item>
              <list-item>
                <p>
                  <bold>Radiographic</bold>
                </p>
              </list-item>
              <list-item>
                <p>Cerebral atrophy</p>
              </list-item>
              <list-item>
                <p>Cerebellar atrophy</p>
              </list-item>
              <list-item>
                <p>Abnormal brain iron accumulation in the globus pallidus, substantia nigra, and/or striatum; findings are variable and may not be evident on MRI studies until late in the disease course for some individuals.</p>
              </list-item>
              <list-item>
                <p>Reduced dopamine transporter labeling similar to that seen in idiopathic Parkinson disease</p>
              </list-item>
              <list-item>
                <p>In some individuals, frontotemporal atrophy/hypoperfusion on single-photon emission computed tomography</p>
              </list-item>
            </list>
          </sec>
        </sec>
        <sec id="inad.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of <italic toggle="yes">PLA2G6</italic>-associated neurodegeneration (PLAN) <bold>is established</bold> in a proband by identification of biallelic pathogenic variants in <italic toggle="yes">PLA2G6</italic> on molecular genetic testing (see <xref ref-type="table" rid="inad.T.molecular_genetic_testing_used_in">Table 1</xref>).</p>
          <p>Molecular genetic testing approaches can include <bold>single-gene testing</bold>, use of a <bold>multi-gene panel</bold>, and <bold>more comprehensive genomic testing</bold>.</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Single-gene testing.</bold> Sequence analysis of <italic toggle="yes">PLA2G6</italic> is performed first and followed by gene-targeted deletion/duplication analysis if only one or no pathogenic variant is found.</p>
            </list-item>
            <list-item>
              <p><bold>A multi-gene panel</bold> that includes <italic toggle="yes">PLA2G6</italic> and other genes of interest (see <xref ref-type="sec" rid="inad.Differential_Diagnosis">Differential Diagnosis</xref>) may also be considered. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and over time. (2) Some multi-gene panels may include genes not associated with the condition discussed in this <italic toggle="yes">GeneReview</italic>; thus, clinicians need to determine which multi-gene panel provides the best opportunity to identify the genetic cause of the condition at the most reasonable cost while limiting secondary findings. (3) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing based tests.</p>
              <p>For more information on multi-gene panels click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.MultiGene_Panels" object-type="sec">here</related-object>.</p>
            </list-item>
            <list-item>
              <p><bold>More comprehensive genomic testing</bold> (when available) including exome sequencing and genome sequencing may be considered. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different gene or genes that results in a similar clinical presentation). For more information on comprehensive genome sequencing click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.Comprehensive_Genome_Sequencing" object-type="sec">here</related-object>.</p>
            </list-item>
          </list>
          <table-wrap id="inad.T.molecular_genetic_testing_used_in" orientation="portrait" position="anchor">
            <label>Table 1. </label>
            <caption>
              <p>Molecular Genetic Testing Used in <italic toggle="yes">PLA2G6</italic>-associated neurodegeneration</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_inad.T.molecular_genetic_testing_used_in_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_inad.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                  <th id="hd_h_inad.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_inad.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">PLA2G6</italic>
                  </td>
                  <td headers="hd_h_inad.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_inad.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">~85%&#x000a0;<sup>4</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_inad.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>5</sup></td>
                  <td headers="hd_h_inad.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x02264;12.5%&#x000a0;<sup>6</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_inad.T.molecular_genetic_testing_used_in_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Unknown&#x000a0;<sup>7</sup></td>
                  <td headers="hd_h_inad.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">NA</td>
                  <td headers="hd_h_inad.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="inad.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="inad" object-id="inad.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="inad.TF.1.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="inad.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
              </fn>
              <fn id="inad.TF.1.3">
                <label>3. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="inad.TF.1.4">
                <label>4. </label>
                <p>Of all individuals identified with <italic toggle="yes">PLA2G6</italic> pathogenic variants, approximately 10% have only one pathogenic variant identified [NBIA International Mutation Database, unpublished data].</p>
              </fn>
              <fn id="inad.TF.1.5">
                <label>5. </label>
                <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
              </fn>
              <fn id="inad.TF.1.6">
                <label>6. </label>
                <p>Deletion and duplication of multiple exons have been identified <xref ref-type="bibr" rid="inad.REF.crompton.2010.207">Crompton et al [2010]</xref> (see <xref ref-type="sec" rid="inad.Molecular_Genetics">Molecular Genetics</xref>, <bold>Pathogenic variants</bold>).</p>
              </fn>
              <fn id="inad.TF.1.7">
                <label>7. </label>
                <p>Linkage data support the presence of at least one additional INAD locus [<xref ref-type="bibr" rid="inad.REF.morgan.2006.752">Morgan et al 2006</xref>].</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Tissue biopsy.</bold> If no <italic toggle="yes">PLA2G6</italic> pathogenic variants are identified but the evolving phenotype remains most consistent with INAD or atypical NAD, a biopsy for identification of dystrophic axons (axonal spheroids) can be considered. Electron microscopic (EM) examination of nerve ultrastructure should be done on one of the following preferred tissues: conjunctiva, skin, rectum, muscle, or other peripheral nerve (sural). Histopathologic evidence of dystrophic axons on biopsy from one or more of the following tissues, viewed by EM, includes:</p>
          <list list-type="bullet">
            <list-item>
              <p>Membranotubular profiles;</p>
            </list-item>
            <list-item>
              <p>Mitochondrial aggregates;</p>
            </list-item>
            <list-item>
              <p>Increased axonal diameter and thinned membrane.</p>
            </list-item>
          </list>
          <p>Note: (1) Because axonal spheroids accumulate with age and may not be evident in all tissues, individuals suspected to have INAD or atypical NAD without identifiable <italic toggle="yes">PLA2G6</italic> pathogenic variants may require multiple biopsies over time before axonal spheroids are identified. (2) Peripheral spheroids have not been described in pathologic specimens from persons with <italic toggle="yes">PLA2G6</italic>-associated dystonia-parkinsonism; however, limited pathologic material has been available thus far from this group.</p>
        </sec>
      </sec>
      <sec id="inad.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="inad.Clinical_Description">
          <title>Clinical Description</title>
          <p><bold>Infantile neuroaxonal dystrophy</bold>
<bold>(INAD).</bold> Onset of INAD usually occurs between ages six months and three years. The disease presents with psychomotor regression (i.e., loss of previously acquired milestones) or delay, delayed walking, or gait disturbance. A single individual with neonatal onset has been reported, with severe hypotonia and marked weakness [<xref ref-type="bibr" rid="inad.REF.fusco.2015.368">Fusco et al 2015</xref>].</p>
          <p>Truncal hypotonia is observed early in the disease course. Over time, affected persons develop a spastic tetraparesis, with symmetric pyramidal tract signs on clinical examination.</p>
          <p>Visual signs and symptoms are common. Strabismus and nystagmus are early features of the disease. Later optic atrophy occurs in most individuals. Optic atrophy may be observed early as optic nerve pallor; thin optic chiasm and tracts have also been reported on brain MRI [<xref ref-type="bibr" rid="inad.REF.farina.1999.376">Farina et al 1999</xref>].</p>
          <p>Seizures occur in a minority of individuals as a later symptom [<xref ref-type="bibr" rid="inad.REF.nardocci.1999.1472">Nardocci et al 1999</xref>, <xref ref-type="bibr" rid="inad.REF.wu.2009.240">Wu et al 2009</xref>].</p>
          <p>Autonomic involvement may present early as constipation or cold extremities. With progression, some individuals require body temperature monitors because of dangerous fluctuations in core body temperature.</p>
          <p>The progression of disease is usually rapid. Many affected children never learn to walk or lose this ability shortly after attaining it. During the end stages of disease, severe spasticity, progressive cognitive decline, and visual impairment result in a vegetative state. Death occurs as a result of secondary illnesses such as aspiration pneumonia, associated with bulbar dysfunction. Many affected children do not survive beyond their first decade, but some survive into their teens or later. Supportive care can contribute to a longer life span by reducing the risk of infection and other complications.</p>
          <p><bold>Atypical NAD.</bold> Whereas the features of INAD are relatively homogeneous, atypical disease is quite varied.</p>
          <p>In general, onset in atypical NAD is in early childhood but can be as late as the late teens. In a series of 13 individuals, four had onset by age three years but a fairly stable course during early childhood resembling static encephalopathy, followed by neurologic deterioration between ages seven and 12 years [<xref ref-type="bibr" rid="inad.REF.nardocci.1999.1472">Nardocci et al 1999</xref>].</p>
          <p>The presenting signs and symptoms may be similar to INAD, including gait instability or ataxia. Others may present with speech delay and autistic features, which may remain as the only evidence of disease for a year or more, given the slow progression of atypical NAD compared to INAD [<xref ref-type="bibr" rid="inad.REF.gregory.2008.1402">Gregory et al 2008</xref>].</p>
          <p>Although spastic tetraparesis is evident late in the disease, it is rarely preceded by early truncal hypotonia. In contrast to classic disease, extrapyramidal findings (i.e., dystonia and dysarthria) predominate in atypical NAD. Eye findings are similar to those seen in classic INAD. Neuropsychiatric disturbances including impulsivity, poor attention span, hyperactivity, and emotional lability are also common [<xref ref-type="bibr" rid="inad.REF.gregory.2008.1402">Gregory et al 2008</xref>].</p>
          <p>Atypical NAD is rare, and the life span is not known; however, it is expected to be longer than that observed in classic disease.</p>
          <p><bold><italic toggle="yes">PLA2G6</italic>-related dystonia-parkinsonism.</bold> To date, only a small number of affected individuals have been described [<xref ref-type="bibr" rid="inad.REF.karkheiran.2015.317">Karkheiran et al 2015</xref>]. Age at onset has varied from four to 37 years [<xref ref-type="bibr" rid="inad.REF.pais_nruiz.2009.19">Pais&#x000e1;n-Ruiz et al 2009</xref>, <xref ref-type="bibr" rid="inad.REF.pais_nruiz.2010.1791">Pais&#x000e1;n-Ruiz et al 2010</xref>, <xref ref-type="bibr" rid="inad.REF.yoshino.2010.1356">Yoshino et al 2010</xref>, <xref ref-type="bibr" rid="inad.REF.bower.2011.1768">Bower et al 2011</xref>, <xref ref-type="bibr" rid="inad.REF.pais_nruiz.2012.814">Pais&#x000e1;n-Ruiz et al 2012</xref>, <xref ref-type="bibr" rid="inad.REF.virmani.2014.245">Virmani et al 2014</xref>]; however, the majority have presented in early adulthood (late teens to 20s). Of those with childhood onset, one presented with foot drag and dystonia at age ten years and the other two children presented with an unsteady gait at ages six and eight years. The youngest individual presented with stuttering speech, clumsiness, and dyslexia at age four years &#x02013; findings which may not be related to the <italic toggle="yes">PLA2G6</italic>-associated neurodegeneration (PLAN). In young adults, initial symptoms are frequently neuropsychiatric, including depression, personality changes, aggression, delusions, or paranoia. Gait disturbance is also common at presentation.</p>
          <p>Regardless of the age at onset, affected individuals consistently develop dystonia and parkinsonism (which may be accompanied by rapid cognitive decline) in their late teens to early twenties. Neuropsychiatric changes may precede the movement disorder or occur concomitantly. Dystonia is most common in the hands and feet but may be more generalized. The most common features of parkinsonism in these individuals are bradykinesia, resting tremor, rigidity, and postural instability. Of note, it is common to have an initially dramatic positive response to dopaminergic agents; however, this tends to be short-lived and followed quickly by the development of motor fluctuations and dyskinesias.</p>
          <p><bold>Neuropathology.</bold>
<xref ref-type="bibr" rid="inad.REF.pais_nruiz.2012.814">Pais&#x000e1;n-Ruiz et al [2012]</xref> described the neuropathologic findings in seven individuals who spanned the three forms of PLAN. Numerous axonal swellings in the basal ganglia and brain stem were observed in individuals with infantile-onset and adult-onset PLAN. They were also found in the spinal cord in the two individuals for whom cord tissue was available. Lewy bodies were widespread in both those with adult-onset and those with infantile-onset PLAN. In two affected individuals, one with onset at 18 years and the other only specified as &#x0201c;childhood,&#x0201d; the Lewy body pathology was comparable to that seen in severe, end-stage Parkinson disease. Tau pathology, to varying degrees, was also found across the PLAN spectrum.</p>
        </sec>
        <sec id="inad.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>Genotype correlates with phenotype to a limited extent:</p>
          <list list-type="bullet">
            <list-item>
              <p>All individuals with two null alleles of <italic toggle="yes">PLA2G6</italic> have INAD.</p>
            </list-item>
            <list-item>
              <p>The less severe atypical NAD phenotype is caused almost exclusively by pathogenic missense variants.</p>
            </list-item>
            <list-item>
              <p>Common pathogenic variants associated with INAD impair the catalytic activity of the PLA2G6 protein, whereas three pathogenic variants associated with <italic toggle="yes">PLA2G6</italic>-related dystonia-parkinsonism did not [<xref ref-type="bibr" rid="inad.REF.engel.2010.e12897">Engel et al 2010</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="inad.Nomenclature">
          <title>Nomenclature</title>
          <p>
            <bold>Outdated terms</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><xref ref-type="bibr" rid="inad.REF.seitelberger.1952">Seitelberger [1952]</xref> first described this condition, which was originally named Seitelberger disease.</p>
            </list-item>
            <list-item>
              <p>Karak syndrome was described in two sibs with early-onset cerebellar ataxia, dystonia, spasticity, and intellectual decline. Brain MRI findings included cerebellar atrophy and iron accumulation in the globus pallidus and substantia nigra [<xref ref-type="bibr" rid="inad.REF.mubaidin.2003.543">Mubaidin et al 2003</xref>]. <xref ref-type="bibr" rid="inad.REF.morgan.2006.752">Morgan et al [2006]</xref> identified pathogenic variants in <italic toggle="yes">PLA2G6</italic> in individuals with Karak syndrome, which is now included in the phenotypic spectrum of PLAN and no longer considered a clinically distinct entity; what had been described as Karak syndrome is now referred to as atypical NAD.</p>
            </list-item>
          </list>
          <p><bold>Current nomenclature.</bold> In addition to INAD, later-onset variants have been called late-infantile, juvenile, or atypical neuroaxonal dystrophy and <related-object link-type="booklink" source-id="gene" document-id="nbia-ov" document-type="chapter">neurodegeneration with brain iron accumulation</related-object> (NBIA).</p>
          <p>The authors propose the following usage:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>INAD</bold> for early-onset, rapidly progressive disease</p>
            </list-item>
            <list-item>
              <p><bold>Atypical NAD</bold> for later childhood-onset disease with slower progression and predominant extrapyramidal findings (dystonia, dysarthria). The atypical NAD phenotype is expected to include a broad range of presentations including Karak syndrome.</p>
            </list-item>
            <list-item>
              <p><bold><italic toggle="yes">PLA2G6-</italic>related dystonia-parkinsonism</bold> for adult-onset dystonia-parkinsonism accompanied by cognitive decline and neuropsychiatric changes</p>
            </list-item>
          </list>
        </sec>
        <sec id="inad.Prevalence">
          <title>Prevalence</title>
          <p>Disease prevalence is not established; it is estimated at 1:1,000,000.</p>
        </sec>
      </sec>
      <sec id="inad.Genetically_Related_Allelic_Disorde">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>Though still only speculative, pathogenic variants in <italic toggle="yes">PLA2G6</italic> may underlie Schindler disease as well. This may explain the discordance between the clinical and biochemical phenotypes observed in Schindler disease, which is categorized as a neuroaxonal dystrophy. Schindler disease was originally reported in sibs with early-onset, rapidly progressive psychomotor regression, evidence of axonal spheroids, and deficiency of &#x003b1;-N-acetylgalactosaminidase (&#x003b1;-NAGA) [<xref ref-type="bibr" rid="inad.REF.schindler.1989.1735">Schindler et al 1989</xref>]. Alpha-NAGA deficiency underlies the oligosacchariduria found in Schindler disease, but its causal role in the neurologic phenotype has been questioned because other persons with &#x003b1;-NAGA deficiency have a spectrum of clinical findings ranging from angiokeratoma to no abnormalities [<xref ref-type="bibr" rid="inad.REF.keulemans.1996.458">Keulemans et al 1996</xref>, <xref ref-type="bibr" rid="inad.REF.bakker.2001.91">Bakker et al 2001</xref>].</p>
        <p>The authors have proposed that pathogenic variants in <italic toggle="yes">PLA2G6</italic> account for the early-onset neurodegenerative phenotype that occurs in a subset of individuals with Schindler disease based on their common clinical and pathologic features, their interrelatedness, and the proximity of <italic toggle="yes">PLA2G6</italic> to <italic toggle="yes">NAGA</italic> on chromosome 22 [<xref ref-type="bibr" rid="inad.REF.westaway.2007.e64">Westaway et al 2007</xref>]. Molecular genetic testing of samples from the original sibs diagnosed with Schindler disease should resolve this question; such samples have not been available.</p>
      </sec>
      <sec id="inad.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <sec id="inad.Infantile_Neuroaxonal_Dystrophy_INA_1">
          <title>Infantile Neuroaxonal Dystrophy (INAD)</title>
          <p>Early diagnosis is challenging because the initial symptoms of psychomotor regression and progression are also observed in other conditions. The observation of an elevated aspartate aminotransferase/alanine aminotransferase ratio and elevated lactate dehydrogenase in combination with these findings is more suspicious for INAD [<xref ref-type="bibr" rid="inad.REF.kraoua.2016.e24">Kraoua et al 2016</xref>].</p>
          <p>The degree of weakness early in the disease course may initially direct the clinician toward a myopathy or <related-object link-type="booklink" source-id="gene" document-id="sma" document-type="chapter">spinal muscular atrophy</related-object>.</p>
          <p>Cerebellar atrophy can be detected by brain MRI before age two years in some children [<xref ref-type="bibr" rid="inad.REF.farina.1999.376">Farina et al 1999</xref>]. The differential diagnosis for childhood cerebellar atrophy includes infantile <related-object link-type="booklink" source-id="gene" document-id="ncl" document-type="chapter">neuronal ceroid-lipofuscinosis</related-object> (CLN1 disease, Santavuori-Haltia), <related-object link-type="booklink" source-id="gene" document-id="ataxia-telangiectas" document-type="chapter">ataxia-telangiectasia</related-object>, <italic toggle="yes">KIF1A</italic>-associated hereditary spastic paraplegia (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/entry/610357">610357</ext-link>; see also <related-object link-type="booklink" source-id="gene" document-id="hsp" document-type="chapter">Hereditary Spastic Paraplegia Overview</related-object>), and <related-object link-type="booklink" source-id="gene" document-id="ataxias" document-type="chapter">hereditary ataxia</related-object>; however, cerebellar atrophy usually presents later in individuals with these disorders.</p>
          <p>An estimated 40%-50% of individuals with INAD have abnormal iron accumulation in the basal ganglia (primarily the globus pallidus), which is best detected on T<sub>2</sub>-weighted MRI. For this reason, conditions included in the <related-object link-type="booklink" source-id="gene" document-id="nbia-ov" document-type="chapter">neurodegeneration with brain iron accumulation</related-object> (NBIA) category should also be considered in the differential diagnosis of INAD. Individuals with INAD have not been found to have an eye-of-the-tiger sign, which correlates very highly with <related-object link-type="booklink" source-id="gene" document-id="pkan" document-type="chapter">pantothenate kinase-associated neurodegeneration</related-object> (PKAN) [<xref ref-type="bibr" rid="inad.REF.hayflick.2003.33">Hayflick et al 2003</xref>].</p>
          <p>Since the identification of <italic toggle="yes">PLA2G6</italic> pathogenic variants as causative of INAD, the need for invasive nerve biopsy to aid in diagnosis has decreased. While the presence of axonal spheroids in peripheral tissues remains specific to INAD, spheroids are found in the brain in a few other conditions, including PKAN, idiopathic NBIA, infantile GM2 gangliosidosis (see <related-object link-type="booklink" source-id="gene" document-id="tay-sachs" document-type="chapter">Hexosaminidase A Deficiency</related-object>), <related-object link-type="booklink" source-id="gene" document-id="npc" document-type="chapter">Niemann-Pick disease type C</related-object>, and Menkes disease (see <related-object link-type="booklink" source-id="gene" document-id="menkes" document-type="chapter"><italic toggle="yes">ATP7A</italic>-Related Copper Transport Disorders</related-object>).</p>
        </sec>
        <sec id="inad.Atypical_Neuroaxonal_Dystrophy_NAD_1">
          <title>Atypical Neuroaxonal Dystrophy (NAD)</title>
          <p>Initial speech delay and limited social interaction may be consistent with autism.</p>
          <p>Spasticity, dystonia, and dysarthria &#x02013; findings similar to those of other forms of NBIA &#x02013; eventually predominate; high brain iron in the globus pallidus and substantia nigra has been observed in nearly all individuals, although ascertainment is likely to be biased [<xref ref-type="bibr" rid="inad.REF.gregory.2008.1402">Gregory et al 2008</xref>]. Therefore, idiopathic NBIA should also be considered in the differential diagnosis of atypical NAD. <related-object link-type="booklink" source-id="gene" document-id="pkan" document-type="chapter">PKAN</related-object> may present with similar features.</p>
        </sec>
        <sec id="inad.PLA2G6Related_DystoniaParkinsonism_1">
          <title><italic toggle="yes">PLA2G6</italic>-Related Dystonia-Parkinsonism</title>
          <p>When high brain iron is present and pathogenic variants in <italic toggle="yes">PLA2G6</italic> have not been identified, other forms of NBIA should be considered in the differential diagnosis. Atypical PKAN, Kufor-Rakeb syndrome (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/606693">606693</ext-link>), MPAN (<related-object link-type="booklink" source-id="gene" document-id="mt-mpan" document-type="chapter">mitochondrial membrane protein-associated neurodegeneration</related-object>), and BPAN (<related-object link-type="booklink" source-id="gene" document-id="bpan" document-type="chapter">beta-propeller protein-associated neurodegeneration</related-object>) can present with neuropsychiatric changes, parkinsonism, and dystonia in late childhood or early adulthood. As in <italic toggle="yes">PLA2G6</italic>-related dystonia-parkinsonism, individuals with MPAN, BPAN, and Kufor-Rakeb syndrome also exhibit cognitive decline.</p>
          <p>Other forms of early-onset dystonia-parkinsonism must also be considered, including: <related-object link-type="booklink" source-id="gene" document-id="drd" document-type="chapter">dopa-responsive dystonia</related-object>; <related-object link-type="booklink" source-id="gene" document-id="wilson" document-type="chapter">Wilson disease</related-object>; Parkinson disease 2 (<related-object link-type="booklink" source-id="gene" document-id="jpd" document-type="chapter">PARK2</related-object>); PARK6, PARK7, and PARK15 (see <related-object link-type="booklink" source-id="gene" document-id="parkinson-overview" document-type="chapter">Parkinson Disease Overview</related-object>); <italic toggle="yes">SLC6A3</italic>-related dystonia-parkinsonism (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/613135">613135</ext-link>); <related-object link-type="booklink" source-id="gene" document-id="xdp" document-type="chapter">X-linked dystonia-parkinsonism</related-object> (DYT-TAF1); <related-object link-type="booklink" source-id="gene" document-id="rapid-odp" document-type="chapter">DYT-ATP1A3</related-object>; DYT16; and <related-object link-type="booklink" source-id="gene" document-id="spg11" document-type="chapter">spastic paraplegia 11</related-object> (SPG11) [<xref ref-type="bibr" rid="inad.REF.schneider.2010.431">Schneider &#x00026; Bhatia 2010</xref>].</p>
        </sec>
      </sec>
      <sec id="inad.Management">
        <title>Management</title>
        <sec id="inad.Evaluations_Following_Initial_Diagn">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with <italic toggle="yes">PLA2G6</italic>-associated neurodegeneration (PLAN), the following evaluations are recommended if they have not already been completed:</p>
          <list list-type="bullet">
            <list-item>
              <p>Thorough ophthalmologic examination to assess for optic atrophy</p>
            </list-item>
            <list-item>
              <p>EEG for the possibility of unrecognized seizure activity</p>
            </list-item>
            <list-item>
              <p>Consultation with a clinical geneticist and/or genetic counselor</p>
            </list-item>
          </list>
          <p>Note: The extent of disease is often well characterized by the time of diagnosis, since the diagnostic work up frequently includes neurophysiologic studies (EEG, EMG, nerve conduction studies, ERG [electroretinogram], and/or VEP) and brain MRI.</p>
        </sec>
        <sec id="inad.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>The following treatments for <bold>infantile neuroaxonal dystrophy</bold> (<bold>INAD)</bold> and <bold>atypical NAD</bold> are palliative:</p>
          <list list-type="bullet">
            <list-item>
              <p>Pharmacologic treatment of spasticity and seizures</p>
            </list-item>
            <list-item>
              <p>Trial of oral or intrathecal baclofen for those with atypical INAD who have significant dystonia (see <related-object link-type="booklink" source-id="gene" document-id="dystonia-ov" document-type="chapter">Dystonia Overview</related-object>)</p>
              <p>Deep brain stimulation has been successfully utilized in one individual with atypical NAD who had intractable dystonia [<xref ref-type="bibr" rid="inad.REF.cif.2014.128">Cif et al 2014</xref>].</p>
            </list-item>
            <list-item>
              <p>Treatment by a psychiatrist for those with a later-onset, more protracted course accompanied by neuropsychiatric symptoms</p>
            </list-item>
            <list-item>
              <p>Over-the-counter fiber supplements and/or stool softeners to treat constipation that is likely caused by a combination of immobility, diet, and medications</p>
            </list-item>
            <list-item>
              <p>Transdermal scopolamine patch to reduce the volume of secretions in those with excessive drooling or difficulty controlling secretions</p>
            </list-item>
            <list-item>
              <p>Measures such as a gastric feeding tube or tracheostomy as needed to prevent aspiration pneumonia</p>
            </list-item>
          </list>
          <p>Treatments for <bold><italic toggle="yes">PLA2G6</italic>-related dystonia-parkinsonism</bold> are also palliative but differ somewhat:</p>
          <list list-type="bullet">
            <list-item>
              <p>Treatment with dopaminergic agents is likely to be beneficial for the motor symptoms of parkinsonism and dystonia and may initially produce a dramatic response. In individuals treated to date, this response diminished over time, and affected individuals often developed prominent early dyskinesias, complicating medical management. Despite the dyskinesias, treatment with dopaminergic agents may still be indicated, as affected individuals typically experience benefit for a period of time and the dyskinesias are expected to decline after discontinuation of treatment. In one case report, an individual age 32 years with dystonia-parkinsonism developed episodes of non-painful, fixed upward gaze with neck extension that started shortly after levodopa administration and persisted until the drug wore off [<xref ref-type="bibr" rid="inad.REF.virmani.2014.245">Virmani et al 2014</xref>]. The use of deep brain stimulation for <italic toggle="yes">PLA2G6</italic>-associated dystonia-parkinsonism has not been reported.</p>
            </list-item>
            <list-item>
              <p>Treatment by a psychiatrist for neuropsychiatric symptoms is indicated.</p>
            </list-item>
            <list-item>
              <p>Evaluation by physical therapy may guide the management of postural instability and gait difficulties.</p>
            </list-item>
            <list-item>
              <p>Occupational therapy may offer tools to assist with activities of daily living.</p>
            </list-item>
            <list-item>
              <p>Interventions such as a gastric feeding tube or tracheostomy may be needed to reduce the risk of aspiration pneumonia.</p>
            </list-item>
          </list>
        </sec>
        <sec id="inad.Prevention_of_Secondary_Complicatio">
          <title>Prevention of Secondary Complications</title>
          <p>A rehabilitation program including physical therapy and orthopedic management should be initiated early in the disease course to prevent contractures when the individual is permanently nonambulatory.</p>
          <p>Body temperature monitors may be required for individuals with progressive autonomic involvement to identify dangerous fluctuations in core body temperature.</p>
        </sec>
        <sec id="inad.Surveillance">
          <title>Surveillance</title>
          <p>Periodic assessment of vision and hearing of nonverbal children is indicated as needed to determine the level of sensory deficits.</p>
        </sec>
        <sec id="inad.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>See <xref ref-type="sec" rid="inad.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="inad.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>Women with the INAD and atypical NAD forms of PLAN have not been known to reproduce due to the relatively early onset and severity of disease.</p>
          <p>Two women with <italic toggle="yes">PLA2G6</italic>-related dystonia-parkinsonism have been reported to reproduce [<xref ref-type="bibr" rid="inad.REF.pais_nruiz.2010.1791">Pais&#x000e1;n-Ruiz et al 2010</xref>, <xref ref-type="bibr" rid="inad.REF.virmani.2014.245">Virmani et al 2014</xref>]. Since onset of manifestations of PLAN has been reported as late as age 30 years, some women may become pregnant before onset of symptoms or early in the disease course. For those who may be symptomatic, the main issue is the potential for teratogenic effects of medications taken during pregnancy. It is not known whether pregnancy itself may have short- or long-term effects on the disease course for the affected pregnant woman.</p>
        </sec>
        <sec id="inad.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Because some individuals with PLAN have high brain iron and this disorder falls into the category of <related-object link-type="booklink" source-id="gene" document-id="nbia-ov" document-type="chapter">NBIA</related-object>, the option of chelation therapy is sometimes raised. The chelator deferiprone is currently under investigation for the PKAN form of NBIA. Results may inform its use in PLAN and/or lead to additional trials.</p>
          <p>A proof-of-concept gene therapy strategy is currently under investigation in murine disease models of PLAN [Dr. Manju Kurian, personal communication].</p>
          <p>Development of small molecule therapies is also under investigation in cell and murine disease models [Dr. Paul Kotzbauer, personal communication].</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
        <sec id="inad.Other">
          <title>Other</title>
          <p><bold>Docosahexaenoic acid (DHA)</bold> is selectively hydrolyzed from phospholipids by the action of the iPLA<sub>2</sub>-beta enzyme, the protein encoded by <italic toggle="yes">PLA2G6.</italic> Although not yet tested as an intervention in individuals with PLAN, a <italic toggle="yes">Pla2g6</italic>-mutant mouse model showed reduced DHA metabolism and signaling [<xref ref-type="bibr" rid="inad.REF.basselin.2010.3166">Basselin et al 2010</xref>]; evidence from a more recent study showed that DHA can reverse selective iPLA<sub>2</sub>-beta inhibition [<xref ref-type="bibr" rid="inad.REF.mazzocchijones.2015.69">Mazzocchi-Jones 2015</xref>]. Given the low risk of harm from DHA supplementation, the authors recommend its administration at a dose that is age appropriate.</p>
        </sec>
      </sec>
      <sec id="inad.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="inad.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p><italic toggle="yes">PLA2G6</italic>-associated neurodegeneration (PLAN) is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="inad.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected individual are obligate heterozygotes (i.e., carriers of one <italic toggle="yes">PLA2G6</italic> pathogenic variant).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</p>
            </list-item>
          </list>
          <p>
            <bold>Offspring of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Individuals with infantile neuroaxonal dystrophy (INAD) and atypical NAD have not been known to reproduce.</p>
            </list-item>
            <list-item>
              <p>All offspring of individuals with later-onset <italic toggle="yes">PLA2G6-</italic>related dystonia-parkinsonism will be obligate (unaffected) carriers.</p>
            </list-item>
            <list-item>
              <p>If the reproductive partner of a person with <italic toggle="yes">PLA2G6-</italic>related dystonia-parkinsonism is a carrier, the risk to their offspring of being homozygous is 50% and of being heterozygous (unaffected carriers) is 50%. The phenotype of the homozygous offspring within the PLAN spectrum will be influenced by the type of pathogenic variant present in the carrier partner; current data are not sufficient to predict which PLAN phenotype the homozygous offspring will display.</p>
            </list-item>
          </list>
          <p><bold>Other family members.</bold> Each sib of the proband&#x02019;s parents is at a 50% risk of being a carrier of a <italic toggle="yes">PLA2G6</italic> pathogenic variant.</p>
        </sec>
        <sec id="inad.Carrier_Heterozygote_Detection">
          <title>Carrier (Heterozygote) Detection</title>
          <p>Carrier testing for at-risk relatives requires prior identification of the <italic toggle="yes">PLA2G6</italic> pathogenic variants in the family.</p>
        </sec>
        <sec id="inad.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p><bold>Testing of at-risk sibs.</bold> The proband may have sibs younger or close in age who could be affected. Although early diagnosis is not likely to significantly reduce morbidity or mortality, testing of at-risk sibs may be desired:</p>
          <list list-type="bullet">
            <list-item>
              <p>If both <italic toggle="yes">PLA2G6</italic> pathogenic variants have been identified in the proband, the sibs may be tested to determine if they have inherited both <italic toggle="yes">PLA2G6</italic> pathogenic variants.</p>
            </list-item>
            <list-item>
              <p>If the <italic toggle="yes">PLA2G6</italic> pathogenic variants have not been identified in the proband, a plan for assessing at-risk sibs should be designed based on the primary findings in the proband and the established clinical criteria for INAD/atypical NAD/<italic toggle="yes">PLA2G6</italic>-related dystonia-parkinsonism. Evaluations are likely to include brain MRI, ophthalmologic assessment, and possibly biopsy for histologic examination of peripheral nerves (<xref ref-type="sec" rid="inad.Diagnosis">see Diagnosis</xref>).</p>
              <p>Note: Neither the absence of axonal spheroids nor a normal brain MRI rules out INAD or atypical NAD, as these findings develop over time and spheroids vary by location. Diagnostic tests may need to be repeated at a later age for at-risk sibs in families without identified <italic toggle="yes">PLA2G6</italic> pathogenic variants. A normal MRI and absence of other symptoms (including regression) in a sib who is older than the affected sib was when cerebellar atrophy and/or other symptoms presented is reassuring.</p>
            </list-item>
            <list-item>
              <p>Predictions of clinical course and age of onset are more challenging in asymptomatic individuals diagnosed with <italic toggle="yes">PLA2G6</italic>-related dystonia-parkinsonism than in individuals with INAD or atypical NAD. Age of onset can vary widely in individuals from the same family; additionally, some of the neuropsychiatric changes that may be present early in disease course (e.g., anxiety or depression) are also common in the general population and thus may not be attributable to the onset of <italic toggle="yes">PLA2G6</italic>-related dystonia-parkinsonism.</p>
            </list-item>
          </list>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="inad.Prenatal_Testing_and_Preimplantatio">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once both <italic toggle="yes">PLA2G6</italic> pathogenic variants have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis for PLAN are possible.</p>
        </sec>
      </sec>
      <sec id="inad.Resources">
        <title>Resources</title>
      </sec>
      <sec id="inad.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="inad.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p><italic toggle="yes">PLA2G6</italic> encodes 85/88-kd calcium-independent phospholipase A<sub>2</sub> (iPLA<sub>2</sub>-VIA). The iPLA<sub>2</sub> family of phospholipase A<sub>2</sub> enzymes catalyzes the hydrolysis of glycerophospholipids, generating a free fatty acid (usually arachidonic acid) and a lysophospholipid. The iPLA<sub>2</sub>-VIA protein has proposed roles in phospholipid remodeling, arachidonic acid release, leukotriene and prostaglandin synthesis, and apoptosis [<xref ref-type="bibr" rid="inad.REF.balsinde.2005.1052">Balsinde &#x00026; Balboa 2005</xref>]. The iPLA<sub>2</sub> enzymes play a critical role in cell membrane homeostasis by helping to regulate levels of phospholipids [<xref ref-type="bibr" rid="inad.REF.baburina.1999.9400">Baburina &#x00026; Jackowski 1999</xref>]. Defects in iPLA<sub>2</sub>-VIA could lead to a relative abundance of membrane phospholipids or skewing of the proportions of specific species and secondary structural abnormalities, which may contribute to the axonal pathology observed in INAD [<xref ref-type="bibr" rid="inad.REF.morgan.2006.752">Morgan et al 2006</xref>].</p>
          <p><bold>Gene structure.</bold> The longest characterized <italic toggle="yes">PLA2G6</italic> transcript (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_003560.2">NM_003560.2</ext-link>) has 17 exons that are alternatively spliced to create several transcript variants encoding multiple protein isoforms [<xref ref-type="bibr" rid="inad.REF.larsson.1998.207">Larsson et al 1998</xref>]. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="inad" object-id="inad.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
          <p><bold>Benign variants.</bold> No commonly occurring <italic toggle="yes">PLA2G6</italic> benign variants have been identified to date.</p>
          <p><bold>Pathogenic variants.</bold> The original report of pathogenic variants in <italic toggle="yes">PLA2G6</italic> described 44 unique pathogenic variants: 32 missense variants, five small deletions leading to a frameshift, three nonsense variants, two leading to amino-acid deletions without a frameshift, one splice site variant, and one contiguous gene deletion [<xref ref-type="bibr" rid="inad.REF.morgan.2006.752">Morgan et al 2006</xref>]. Multiexon deletion and duplication have been identified in several individuals [<xref ref-type="bibr" rid="inad.REF.crompton.2010.207">Crompton et al 2010</xref>, <xref ref-type="bibr" rid="inad.REF.tonelli.2010.432">Tonelli et al 2010</xref>, <xref ref-type="bibr" rid="inad.REF.yamamoto.2015.15048">Yamamoto et al 2015</xref>]. Some pathogenic variants have been identified in multiple families reported to be unrelated, although several share ethnic backgrounds [NBIA International Mutation Database, unpublished data]. A founder variant, p.Val691del, has been described in a North African cohort [<xref ref-type="bibr" rid="inad.REF.romani.2015.178">Romani et al 2015</xref>].</p>
          <table-wrap id="inad.T.pla2g6_pathogenic_variants_discus" orientation="portrait" position="anchor">
            <label>Table 2. </label>
            <caption>
              <p><italic toggle="yes">PLA2G6</italic> Pathogenic Variants Discussed in This <italic toggle="yes">GeneReview</italic></p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_inad.T.pla2g6_pathogenic_variants_discus_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                  <th id="hd_h_inad.T.pla2g6_pathogenic_variants_discus_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                  <th id="hd_h_inad.T.pla2g6_pathogenic_variants_discus_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_inad.T.pla2g6_pathogenic_variants_discus_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.2070_2072del</td>
                  <td headers="hd_h_inad.T.pla2g6_pathogenic_variants_discus_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Val691del</td>
                  <td headers="hd_h_inad.T.pla2g6_pathogenic_variants_discus_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_003560.2">NM_003560.2</ext-link>
                    <break/>
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_003551.2">NP_003551.2</ext-link>
                  </td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
              </fn>
              <fn>
                <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Normal gene product.</bold> The longest transcript (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_003560.2">NM_003560.2</ext-link>) encodes a protein of 806 amino acids (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_003551.2">NP_003551.2</ext-link>). iPLA<sub>2</sub>-VIA is one of several calcium-independent phospholipases. The protein is active as a tetramer.</p>
          <p><bold>Abnormal gene product.</bold> The two enzymatically active isoforms of the protein are predicted to be affected by all of the pathogenic variants reported to date [<xref ref-type="bibr" rid="inad.REF.morgan.2006.752">Morgan et al 2006</xref>]. A subset of pathogenic variants would also alter the shorter enzymatically inactive isoforms, which appear to act as dominant-negative inhibitors when incorporated in the tetramer [<xref ref-type="bibr" rid="inad.REF.larsson.1998.207">Larsson et al 1998</xref>, <xref ref-type="bibr" rid="inad.REF.balsinde.2005.1052">Balsinde &#x00026; Balboa 2005</xref>].</p>
        </sec>
      </sec>
      <sec id="inad.References">
        <title>References</title>
        <sec id="inad.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="inad.Literature_Cited.reflist0">
            <ref id="inad.REF.almaawali.2016.1035">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Al-Maawali</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoon</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feigenbaum</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Halliday</surname>
                    <given-names>WC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clarke</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Branson</surname>
                    <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Banwell</surname>
                    <given-names>BL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chitayat</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blaser</surname>
                    <given-names>SI</given-names>
                  </name>
                </person-group>
                <year>2016</year>
                <article-title>Validation of the finding of hypertrophy of the clava in infantile neuroaxonal dystrophy/PLA2G6 by biometric analysis.</article-title>
                <source>Neuroradiology</source>
                <volume>58</volume>
                <fpage>1035</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">27516098</pub-id>
              </element-citation>
            </ref>
            <ref id="inad.REF.baburina.1999.9400">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Baburina</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jackowski</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Cellular responses to excess phospholipid.</article-title>
                <source>J Biol Chem</source>
                <volume>274</volume>
                <fpage>9400</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">10092620</pub-id>
              </element-citation>
            </ref>
            <ref id="inad.REF.bakker.2001.91">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bakker</surname>
                    <given-names>HD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Sonnaville</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vreken</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abeling</surname>
                    <given-names>NG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Groener</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keulemans</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Diggelen</surname>
                    <given-names>OP</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Human alpha-N-acetylgalactosaminidase (alpha-NAGA) deficiency: no association with neuroaxonal dystrophy?</article-title>
                <source>Eur J Hum Genet</source>
                <volume>9</volume>
                <fpage>91</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">11313741</pub-id>
              </element-citation>
            </ref>
            <ref id="inad.REF.balsinde.2005.1052">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Balsinde</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Balboa</surname>
                    <given-names>MA</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Cellular regulation and proposed biological functions of group VIA calcium-independent phospholipase A2 in activated cells.</article-title>
                <source>Cell Signal</source>
                <volume>17</volume>
                <fpage>1052</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">15993747</pub-id>
              </element-citation>
            </ref>
            <ref id="inad.REF.basselin.2010.3166">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Basselin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosa</surname>
                    <given-names>AO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramadan</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cheon</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chang</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Greenstein</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wohltmann</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turk</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rapoport</surname>
                    <given-names>SI</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Imaging decreased brain docosahexaenoic acid metabolism and signaling in iPLA2B (VIA)-deficient mice.</article-title>
                <source>J Lipid Res</source>
                <volume>51</volume>
                <fpage>3166</fpage>
                <lpage>73</lpage>
                <pub-id pub-id-type="pmid">20686114</pub-id>
              </element-citation>
            </ref>
            <ref id="inad.REF.bower.2011.1768">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bower</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bushara</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dempsey</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Das</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tuite</surname>
                    <given-names>PJ</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Novel mutations in siblings with later-onset PLA2G6-associated neurodegeneration (PLAN).</article-title>
                <source>Mov Disord</source>
                <volume>26</volume>
                <fpage>1768</fpage>
                <lpage>69</lpage>
                <pub-id pub-id-type="pmid">21520282</pub-id>
              </element-citation>
            </ref>
            <ref id="inad.REF.cif.2014.128">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cif</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kurian</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gonzalez</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garcia-Ptacek</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roujeau</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gelisse</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moura de Ribeiro</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crespel</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Macpherson</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coubes</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>Atypical PLA2G6-associated neurodegeneration: social communication impairment, dystonia and response to deep brain stimulation.</article-title>
                <source>Mov Disord Clin Pract.</source>
                <year>2014</year>
                <volume>1</volume>
                <fpage>128</fpage>
                <lpage>31</lpage>
              </element-citation>
            </ref>
            <ref id="inad.REF.crompton.2010.207">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Crompton</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rehal</surname>
                    <given-names>PK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>MacPherson</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Foster</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lunt</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hughes</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brady</surname>
                    <given-names>AF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pike</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Gressi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morgan</surname>
                    <given-names>NV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hardy</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>MacDonald</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maher</surname>
                    <given-names>ER</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kurian</surname>
                    <given-names>MA</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Multiplex ligation-dependent probe amplification (MLPA) analysis is an effective tool for the detection of novel intragenic PLA2G6 mutations: implications for molecular diagnosis.</article-title>
                <source>Mol Genet Metab.</source>
                <volume>100</volume>
                <fpage>207</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">20226704</pub-id>
              </element-citation>
            </ref>
            <ref id="inad.REF.engel.2010.e12897">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Engel</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jing</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Brien</surname>
                    <given-names>DE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sun</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kotzbauer</surname>
                    <given-names>PT</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Catalytic function of PLA2G6 is impaired by mutations associated with infantile neuroaxonal dystrophy but not dystonia-parkinsonism.</article-title>
                <source>PLoS One.</source>
                <volume>5</volume>
                <fpage>e12897</fpage>
                <pub-id pub-id-type="pmid">20886109</pub-id>
              </element-citation>
            </ref>
            <ref id="inad.REF.farina.1999.376">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Farina</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nardocci</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruzzone</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D'Incerti</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zorzi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verga</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morbin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Savoiardo</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Infantile neuroaxonal dystrophy: neuroradiological studies in 11 patients.</article-title>
                <source>Neuroradiology</source>
                <volume>41</volume>
                <fpage>376</fpage>
                <lpage>80</lpage>
                <pub-id pub-id-type="pmid">10379598</pub-id>
              </element-citation>
            </ref>
            <ref id="inad.REF.fusco.2015.368">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fusco</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frattini</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Panteghini</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pascarella</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garavaglia</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2015</year>
                <article-title>A case of infantile neuroaxonal dystrophy of neonatal onset.</article-title>
                <source>J Child Neurol</source>
                <volume>30</volume>
                <fpage>368</fpage>
                <lpage>70</lpage>
                <pub-id pub-id-type="pmid">24870368</pub-id>
              </element-citation>
            </ref>
            <ref id="inad.REF.gregory.2008.1402">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gregory</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Westaway</surname>
                    <given-names>SK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holm</surname>
                    <given-names>IE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kotzbauer</surname>
                    <given-names>PT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hogarth</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sonek</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coryell</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nguyen</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nardocci</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zorzi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodriguez</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desguerre</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simonati</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levinson</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dias</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barbot</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carrilho</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santos</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malik</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gitschier</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayflick</surname>
                    <given-names>SJ</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Neurodegeneration associated with genetic defects in phospholipase A2.</article-title>
                <source>Neurology</source>
                <volume>71</volume>
                <fpage>1402</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">18799783</pub-id>
              </element-citation>
            </ref>
            <ref id="inad.REF.hayflick.2003.33">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hayflick</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Westaway</surname>
                    <given-names>SK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levinson</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhou</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ching</surname>
                    <given-names>KH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gitschier</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome.</article-title>
                <source>N Engl J Med</source>
                <volume>348</volume>
                <fpage>33</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">12510040</pub-id>
              </element-citation>
            </ref>
            <ref id="inad.REF.illingworth.2014.183">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Illingworth</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meyer</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chong</surname>
                    <given-names>WK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manzur</surname>
                    <given-names>AY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carr</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Younis</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hardy</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McDonald</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Childs</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stewart</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Warren</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kneen</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>King</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayflick</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kurian</surname>
                    <given-names>MA</given-names>
                  </name>
                </person-group>
                <article-title>PLA2G6-associated neurodegeneration (PLAN): further expansion of the clinical, radiological and mutation spectrum associated with infantile and atypical childhood-onset disease.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2014</year>
                <volume>112</volume>
                <fpage>183</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">24745848</pub-id>
              </element-citation>
            </ref>
            <ref id="inad.REF.karkheiran.2015.317">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Karkheiran</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shahidi</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walker</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pais&#x000e1;n-Ruiz</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>PLA2G6-associated Dystonia-Parkinsonism: Case Report and Literature Review.</article-title>
                <source>Tremor Other Hyperkinet Mov (N Y)</source>
                <year>2015</year>
                <month>Jul</month>
                <day>10</day>
                <volume>5</volume>
                <fpage>317</fpage>
                <pub-id pub-id-type="pmid">26196026</pub-id>
              </element-citation>
            </ref>
            <ref id="inad.REF.keulemans.1996.458">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Keulemans</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reuser</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kroos</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Willemsen</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hermans</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van den Ouweland</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Jong</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wevers</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Renier</surname>
                    <given-names>WO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schindler</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coll</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chabas</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sakuraba</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Diggelen</surname>
                    <given-names>OP</given-names>
                  </name>
                </person-group>
                <year>1996</year>
                <article-title>Human alpha-N-acetylgalactosaminidase (alpha-NAGA) deficiency: new mutations and the paradox between genotype and phenotype.</article-title>
                <source>J Med Genet</source>
                <volume>33</volume>
                <fpage>458</fpage>
                <lpage>64</lpage>
                <pub-id pub-id-type="pmid">8782044</pub-id>
              </element-citation>
            </ref>
            <ref id="inad.REF.kraoua.2016.e24">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kraoua</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Romani</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tonduti</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>BenRhouma</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zorzi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zibordi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ardissone</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gouider-Khouja</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ben Youssef-Turki</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nardocci</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valente</surname>
                    <given-names>EM</given-names>
                  </name>
                </person-group>
                <year>2016</year>
                <article-title>Elevated aspartate aminotransferase and lactate dehydrogenase levels are a constant finding in PLA2G6-associated neurodegeneration.</article-title>
                <source>Eur J Neurol</source>
                <volume>23</volume>
                <fpage>e24</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">27000981</pub-id>
              </element-citation>
            </ref>
            <ref id="inad.REF.larsson.1998.207">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Larsson</surname>
                    <given-names>PK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Claesson</surname>
                    <given-names>HE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kennedy</surname>
                    <given-names>BP</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Multiple splice variants of the human calcium-independent phospholipase A2 and their effect on enzyme activity.</article-title>
                <source>J Biol Chem</source>
                <volume>273</volume>
                <fpage>207</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">9417066</pub-id>
              </element-citation>
            </ref>
            <ref id="inad.REF.mazzocchijones.2015.69">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mazzocchi-Jones</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2015</year>
                <article-title>Impaired corticostriatal LTP and depotentiation following iPLA2 inhibition is restored following acute application of DHA.</article-title>
                <source>Brain Res Bull</source>
                <volume>111</volume>
                <fpage>69</fpage>
                <lpage>75</lpage>
                <pub-id pub-id-type="pmid">25562715</pub-id>
              </element-citation>
            </ref>
            <ref id="inad.REF.morgan.2006.752">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Morgan</surname>
                    <given-names>NV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Westaway</surname>
                    <given-names>SK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morton</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gregory</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gissen</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sonek</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cangul</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coryell</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Canham</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nardocci</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zorzi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pasha</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodriguez</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desguerre</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mubaidin</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trembath</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simonati</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schanen</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levinson</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Woods</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilmot</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kramer</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gitschier</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maher</surname>
                    <given-names>ER</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayflick</surname>
                    <given-names>SJ</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>PLA2G6, encoding a phospholipase A(2), is mutated in neurodegenerative disorders with high brain iron.</article-title>
                <source>Nat Genet</source>
                <volume>38</volume>
                <fpage>752</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">16783378</pub-id>
              </element-citation>
            </ref>
            <ref id="inad.REF.mubaidin.2003.543">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mubaidin</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roberts</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hampshire</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dehyyat</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shurbaji</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mubaidien</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jamil</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Din</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kurdi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Woods</surname>
                    <given-names>CG</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Karak syndrome: a novel degenerative disorder of the basal ganglia and cerebellum.</article-title>
                <source>J Med Genet</source>
                <volume>40</volume>
                <fpage>543</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">12843330</pub-id>
              </element-citation>
            </ref>
            <ref id="inad.REF.nardocci.1999.1472">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nardocci</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zorzi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Farina</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Binelli</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scaioli</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ciano</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verga</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Angelini</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Savoiardo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bugiani</surname>
                    <given-names>O</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Infantile neuroaxonal dystrophy: clinical spectrum and diagnostic criteria.</article-title>
                <source>Neurology</source>
                <volume>52</volume>
                <fpage>1472</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">10227637</pub-id>
              </element-citation>
            </ref>
            <ref id="inad.REF.pais_nruiz.2009.19">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pais&#x000e1;n-Ruiz</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bhatia</surname>
                    <given-names>KP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hernandez</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davis</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wood</surname>
                    <given-names>NW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hardy</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Houlden</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Singleton</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneider</surname>
                    <given-names>SA</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Characterization of PLA2G6 as a locus for dystonia-parkinsonism.</article-title>
                <source>Ann Neurol.</source>
                <volume>65</volume>
                <fpage>19</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">18570303</pub-id>
              </element-citation>
            </ref>
            <ref id="inad.REF.pais_nruiz.2010.1791">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pais&#x000e1;n-Ruiz</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guevara</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Federoff</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanagasi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sina</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elahi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneider</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwingenschuh</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bajaj</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Emre</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Singleton</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hardy</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bhatia</surname>
                    <given-names>KP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brandner</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lees</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Houldon</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Early-onset L-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBX07, and spatacsin mutations.</article-title>
                <source>Mov Disord</source>
                <volume>25</volume>
                <fpage>1791</fpage>
                <lpage>800</lpage>
                <pub-id pub-id-type="pmid">20669327</pub-id>
              </element-citation>
            </ref>
            <ref id="inad.REF.pais_nruiz.2012.814">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pais&#x000e1;n-Ruiz</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneider</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holton</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kidd</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chataway</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bhatia</surname>
                    <given-names>KP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lees</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hardy</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Revesz</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hould</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations.</article-title>
                <source>Neurobiol Aging.</source>
                <volume>33</volume>
                <fpage>814</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">20619503</pub-id>
              </element-citation>
            </ref>
            <ref id="inad.REF.romani.2015.178">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Romani</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kraoua</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Micalizzi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klaa</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benrhouma</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Drissi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turki</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castellana</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazza</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valente</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gouider-Khouja</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2015</year>
                <article-title>Infantile and childhood onset PLA2G6-associated neurodegeneration in a large North African Cohort.</article-title>
                <source>Eur J Neurol</source>
                <volume>22</volume>
                <fpage>178</fpage>
                <lpage>86</lpage>
                <pub-id pub-id-type="pmid">25164370</pub-id>
              </element-citation>
            </ref>
            <ref id="inad.REF.schindler.1989.1735">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schindler</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bishop</surname>
                    <given-names>DF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wolfe</surname>
                    <given-names>DE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Egge</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lemieux</surname>
                    <given-names>RU</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desnick</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>1989</year>
                <article-title>Neuroaxonal dystrophy due to lysosomal alpha-N-acetylgalactosaminidase deficiency.</article-title>
                <source>N Engl J Med</source>
                <volume>320</volume>
                <fpage>1735</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">2733734</pub-id>
              </element-citation>
            </ref>
            <ref id="inad.REF.schneider.2010.431">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schneider</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bhatia</surname>
                    <given-names>KP</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Rare causes of dystonia parkinsonism.</article-title>
                <source>Curr Neurol Neurosci Rep</source>
                <volume>10</volume>
                <fpage>431</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">20694531</pub-id>
              </element-citation>
            </ref>
            <ref id="inad.REF.seitelberger.1952">
              <mixed-citation publication-type="confproc">Seitelberger F. Eine unbekannte Form von infantiler lipoid-Speicher Krankheit des Gehirns. Paper. Rome, Italy. First International Congress of Neuropathology. 1952.</mixed-citation>
            </ref>
            <ref id="inad.REF.tonelli.2010.432">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tonelli</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Romaniello</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grasso</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cavallini</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Righini</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bresolin</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Borgatti</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bassi</surname>
                    <given-names>MT</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Novel splice-site mutations and a large intragenic deletion in PLA2G6 associated with a severe and rapidly progressive form of infantile neuroaxonal dystrophy.</article-title>
                <source>Clin Genet.</source>
                <year>2010</year>
                <volume>78</volume>
                <fpage>432</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">20584031</pub-id>
              </element-citation>
            </ref>
            <ref id="inad.REF.virmani.2014.245">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Virmani</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thenganatt</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldman</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kubisch</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Greene</surname>
                    <given-names>PE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alcalay</surname>
                    <given-names>RN</given-names>
                  </name>
                </person-group>
                <article-title>Oculogyric crises induced by levodopa in PLA2G6 parkinsonism-dystonia.</article-title>
                <source>Parkinsonism Relat Disord.</source>
                <year>2014</year>
                <volume>20</volume>
                <fpage>245</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">24182522</pub-id>
              </element-citation>
            </ref>
            <ref id="inad.REF.westaway.2007.e64">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Westaway</surname>
                    <given-names>SK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gregory</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayflick</surname>
                    <given-names>SJ</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Mutations in PLA2G6 and the riddle of Schindler disease.</article-title>
                <source>J Med Genet</source>
                <volume>44</volume>
                <fpage>e64</fpage>
                <pub-id pub-id-type="pmid">17209134</pub-id>
              </element-citation>
            </ref>
            <ref id="inad.REF.wu.2009.240">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wu</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jiang</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gao</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yuan</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xiong</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chang</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bao</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xiao</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wu</surname>
                    <given-names>X</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Clinical study and PLA2G6 mutation screening analysis in Chinese patients with infantile neuroaxonal dystrophy.</article-title>
                <source>Eur J Neurol.</source>
                <volume>16</volume>
                <fpage>240</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">19138334</pub-id>
              </element-citation>
            </ref>
            <ref id="inad.REF.yamamoto.2015.15048">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yamamoto</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimojima</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shibata</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Akiyama</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oka</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Akiyama</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshinaga</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kobayashi</surname>
                    <given-names>K.</given-names>
                  </name>
                </person-group>
                <article-title>Novel PLA2G6 mutations associated with an exonic deletion due to non-allelic homologous recombination in a patient with infantile neuroaxonal dystrophy.</article-title>
                <source>Hum Genome Var.</source>
                <year>2015</year>
                <month>Nov</month>
                <day>19</day>
                <volume>2</volume>
                <fpage>15048</fpage>
                <pub-id pub-id-type="pmid">27081553</pub-id>
              </element-citation>
            </ref>
            <ref id="inad.REF.yoshino.2010.1356">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yoshino</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tomiyama</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tachibana</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ogaki</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Funayama</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hashimoto</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takashima</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hattori</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism.</article-title>
                <source>Neurology.</source>
                <volume>75</volume>
                <fpage>1356</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">20938027</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="inad.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="inad.Suggested_Reading.reflist0">
            <ref id="inad.REF.hartig.2011.543">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hartig</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iuso</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haack</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kmiec</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jurkiewicz</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heim</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roeber</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tarabin</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dusi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krajewska-Walasek</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jozwiak</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hempel</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winkelmann</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elstr</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oexle</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klopstock</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mueller-Felber</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gasser</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trenkwalder</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tiranti</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kretzschmar</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmitz</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strom</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meitinger</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prokisch</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Absense of an orphan mitochondrial protein, c19orf12, causes a distinct clinical subtype of neurodegeneration with brain iron accumulation.</article-title>
                <source>Am J Hum Genet</source>
                <volume>89</volume>
                <fpage>543</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">21981780</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="inad.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="inad.Acknowledgments">
          <title>Acknowledgments</title>
          <p>This work was supported in part by grants from the National Institute of Child Health and Human Development, the National Eye Institute, L'Association Internationale de Dystrophie Neuro Axonale Infantile, and the NBIA Disorders Association. This work was made possible by support from the Oregon Clinical and Translational Research Institute (OCTRI), grant number UL1 RR024140 01 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research.</p>
        </sec>
        <sec id="inad.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>23 March 2017 (sw) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>19 March 2015 (ag) Revision: docosahexaenoic acid added as a treatment for PLAN</p>
            </list-item>
            <list-item>
              <p>21 August 2014 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>19 April 2012 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>1 September 2009 (cd) Revision: deletion/duplication analysis available clinically</p>
            </list-item>
            <list-item>
              <p>19 June 2008 (me) Review posted live</p>
            </list-item>
            <list-item>
              <p>14 June 2007 (ag) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec sec-type="figs-and-tables">
        <title/>
        <fig position="float" id="inad.F1" orientation="portrait">
          <label>Figure 1<break/><break/></label>
          <caption>
            <p>A. Left axial image shows high brain iron in the globus pallidus (see arrow) on T<sub>2</sub>-weighted MRI. B. Right sagittal image shows cerebellar atrophy (see arrow).</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="inad-Image001" position="anchor" orientation="portrait"/>
        </fig>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
